Pipeline

The DuoADC™ platform is driving a robust and differentiated pipeline of antibody–drug conjugates that leverage dual-antigen targeting and complementary dual-payload mechanisms to overcome tumor heterogeneity, resistance, and safety limitations seen in conventional ADC therapies. Our portfolio spans solid tumors and hematologic malignancies with high unmet need, and each candidate is designed based on thorough preclinical validation and translational alignment.